Evidence map›Paper›PMID 38506470›Full record

ArticleOrganic letters2024

Expanding Complex Morpholines Using Systematic Chemical Diversity.

Sunny Ann Tang, Afton Fults, Shelton R Boyd, Nikhil Gattu, Kevin A Tran, Jiayi Fan, Kevin R MacKenzie, Timothy Palzkill, Damian W Young, Srinivas Chamakuri

Abstract read
In one paragraph

Article in Organic letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CMolecules (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sunny Ann TangVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
Afton FultsDepartment of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005, United States.ORCID 0000-0002-9241-8521
Shelton R BoydVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
Nikhil GattuDepartment of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005, United States.
Kevin A TranCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
Jiayi FanVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
Kevin R MacKenzieCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.ORCID 0000-0001-9620-5868
Timothy PalzkillVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.ORCID 0000-0002-5267-0001
Damian W YoungCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.ORCID 0000-0002-1595-9658
Srinivas ChamakuriCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.ORCID 0000-0002-7586-4992

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI MING LUO · 2022 to 2026
$100.9M
Discovery of Carbapenemase Inhibitors Using DNA-Encoded Chemical LibrariesR01AI143832 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2019 to 2023
$3.0M
Neutron encoded activity based probesR01GM139295 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI YOUNG, DAMIAN WINSTON, YOUNG, NICOLAS L · 2020 to 2024
$2.2M
Gates Foundation INV-001902NIAID NIH HHS R01 AI143832NIAID NIH HHS U19 AI171954NIGMS NIH HHS R01 GM139295
6 · The paper itself

Abstract

The morpholine heterocycle is a structural unit found in many bioactive compounds and FDA-approved drugs, but the generation of more complex C-functionalized morpholine derivatives remains considerably underexplored. Using systematic chemical diversity (SCD), a concept that guides the expansion of saturated drug-like scaffolds through regiochemical and stereochemical variation, we describe the synthesis of a collection of methyl-substituted morpholine acetic acid esters starting from enantiomerically pure amino acids and amino alcohols. In total, 24 diverse substituted morpholines were produced that vary systematically in regiochemistry and stereochemistry (relative and absolute). These diverse C-substituted morpholines can be directly applied in fragment screening or incorporated as building blocks in medicinal chemistry and library synthesis.

Indexed as

MorpholinesAmino AcidsChemistry, PharmaceuticalEstersMolecular StructureStereoisomerismAmino AcidsEstersMorpholines

Identifiers

PMID38506470
PMCPMC12415967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.